ADVM Adverum Biotechnologies Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ADVM

Price (delayed)

$1.21

Market cap

$121.7M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.46

Enterprise value

$122.99M

Adverum Biotechnologies is a clinical-stage gene therapy company targeting unmet medical needs in serious ocular and rare diseases. Adverum is advancing the clinical development of its novel gene therapy candidate, ...

Highlights
Adverum Biotechnologies's debt has decreased by 29% YoY and by 24% QoQ
ADVM's EPS is up by 7% YoY and by 6% QoQ
The quick ratio has plunged by 70% YoY and by 38% from the previous quarter
Adverum Biotechnologies's equity has decreased by 44% YoY and by 13% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://adverum.com
Peers: OVID

Key stats

What are the main financial stats of ADVM
Market
Shares outstanding
100.57M
Market cap
$121.7M
Enterprise value
$122.99M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.77
Price to sales (P/S)
33.71
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
34.16
Earnings
Revenue
$3.6M
EBIT
-$145.61M
EBITDA
-$137.49M
Free cash flow
-$109.1M
Per share
EPS
-$1.46
Free cash flow per share
-$1.09
Book value per share
$1.57
Revenue per share
$0.04
TBVPS
$2.75
Balance sheet
Total assets
$275.58M
Total liabilities
$117.82M
Debt
$71.35M
Equity
$157.76M
Working capital
$122.4M
Liquidity
Debt to equity
0.45
Current ratio
3.63
Quick ratio
3.59
Net debt/EBITDA
-0.01
Margins
EBITDA margin
-3,819.2%
Gross margin
100%
Net margin
-4,046.8%
Operating margin
-4,145.6%
Efficiency
Return on assets
-45.1%
Return on equity
-73.6%
Return on invested capital
-49%
Return on capital employed
-63.6%
Return on sales
-4,044.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ADVM stock price

How has the Adverum Biotechnologies stock price performed over time
Intraday
6.14%
1 week
21.93%
1 month
61.33%
1 year
31.29%
YTD
108.8%
QTD
68.66%

Financial performance

How have Adverum Biotechnologies's revenue and profit performed over time
Revenue
$3.6M
Gross profit
$3.6M
Operating income
-$149.24M
Net income
-$145.68M
Gross margin
100%
Net margin
-4,046.8%
Adverum Biotechnologies's net income has increased by 6% YoY and by 6% QoQ
ADVM's operating income is up by 5% from the previous quarter and by 4.1% YoY

Growth

What is Adverum Biotechnologies's growth rate over time

Valuation

What is Adverum Biotechnologies stock price valuation
P/E
N/A
P/B
0.77
P/S
33.71
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
34.16
ADVM's EPS is up by 7% YoY and by 6% QoQ
The price to book (P/B) is 93% higher than the last 4 quarters average of 0.4 but 57% lower than the 5-year quarterly average of 1.8
Adverum Biotechnologies's equity has decreased by 44% YoY and by 13% QoQ

Efficiency

How efficient is Adverum Biotechnologies business performance
Adverum Biotechnologies's return on invested capital has shrunk by 58% YoY and by 7% QoQ
Adverum Biotechnologies's return on equity has shrunk by 57% YoY and by 9% QoQ
The company's return on assets fell by 35% YoY and by 3.9% QoQ

Dividends

What is ADVM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ADVM.

Financial health

How did Adverum Biotechnologies financials performed over time
The total assets is 134% greater than the total liabilities
ADVM's current ratio has dropped by 70% year-on-year and by 39% since the previous quarter
The quick ratio has plunged by 70% YoY and by 38% from the previous quarter
Adverum Biotechnologies's debt is 55% lower than its equity
Adverum Biotechnologies's equity has decreased by 44% YoY and by 13% QoQ
Adverum Biotechnologies's debt has decreased by 29% YoY and by 24% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.